Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 102

1.

Cancer immunotherapy: co-stimulatory agonists and co-inhibitory antagonists.

Peggs KS, Quezada SA, Allison JP.

Clin Exp Immunol. 2009 Jul;157(1):9-19. doi: 10.1111/j.1365-2249.2009.03912.x. Epub 2009 Feb 18. Review.

PMID:
19659765
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

[The immunotherapy potential of agonistic anti-CD137 (4-1BB) monoclonal antibodies for malignancies and chronic viral diseases].

Alfaro C, Murillo O, Tirapu I, Azpilicueta A, Huarte E, Arina A, Arribillaga L, Pérez-Gracia JL, Bendandi M, Prieto J, Lasarte JJ, Melero I.

An Sist Sanit Navar. 2006 Jan-Apr;29(1):77-96. Review. Spanish.

PMID:
16670731
[PubMed - indexed for MEDLINE]
Free Article
3.

Cell intrinsic mechanisms of T-cell inhibition and application to cancer therapy.

Peggs KS, Quezada SA, Allison JP.

Immunol Rev. 2008 Aug;224:141-65. doi: 10.1111/j.1600-065X.2008.00649.x. Review.

PMID:
18759925
[PubMed - indexed for MEDLINE]
4.

Modulation of CTLA-4 and GITR for cancer immunotherapy.

Avogadri F, Yuan J, Yang A, Schaer D, Wolchok JD.

Curr Top Microbiol Immunol. 2011;344:211-44. doi: 10.1007/82_2010_49. Review.

PMID:
20563707
[PubMed - indexed for MEDLINE]
Free PMC Article
5.

Therapeutic potential of immunostimulatory monoclonal antibodies.

Gray JC, Johnson PW, Glennie MJ.

Clin Sci (Lond). 2006 Aug;111(2):93-106. Review.

PMID:
16831129
[PubMed - indexed for MEDLINE]
Free Article
6.

Exploiting CTLA-4, PD-1 and PD-L1 to reactivate the host immune response against cancer.

Quezada SA, Peggs KS.

Br J Cancer. 2013 Apr 30;108(8):1560-5. doi: 10.1038/bjc.2013.117. Epub 2013 Mar 19.

PMID:
23511566
[PubMed - indexed for MEDLINE]
Free PMC Article
7.

Modulation of GITR for cancer immunotherapy.

Schaer DA, Murphy JT, Wolchok JD.

Curr Opin Immunol. 2012 Apr;24(2):217-24. doi: 10.1016/j.coi.2011.12.011. Epub 2012 Jan 12. Review.

PMID:
22245556
[PubMed - indexed for MEDLINE]
Free PMC Article
8.

Cancer immunotherapy--revisited.

Lesterhuis WJ, Haanen JB, Punt CJ.

Nat Rev Drug Discov. 2011 Aug 1;10(8):591-600. doi: 10.1038/nrd3500. Review.

PMID:
21804596
[PubMed - indexed for MEDLINE]
9.

Monoclonal antibodies: versatile platforms for cancer immunotherapy.

Weiner LM, Surana R, Wang S.

Nat Rev Immunol. 2010 May;10(5):317-27. doi: 10.1038/nri2744. Review.

PMID:
20414205
[PubMed - indexed for MEDLINE]
Free PMC Article
10.

Two distinct mechanisms of augmented antitumor activity by modulation of immunostimulatory/inhibitory signals.

Mitsui J, Nishikawa H, Muraoka D, Wang L, Noguchi T, Sato E, Kondo S, Allison JP, Sakaguchi S, Old LJ, Kato T, Shiku H.

Clin Cancer Res. 2010 May 15;16(10):2781-91. doi: 10.1158/1078-0432.CCR-09-3243. Epub 2010 May 11.

PMID:
20460483
[PubMed - indexed for MEDLINE]
Free Article
11.

Cytokine, chemokine, and co-stimulatory fusion proteins for the immunotherapy of solid tumors.

Khawli LA, Hu P, Epstein AL.

Handb Exp Pharmacol. 2008;(181):291-328. Review.

PMID:
18071951
[PubMed - indexed for MEDLINE]
12.

Combination of CTL-associated antigen-4 blockade and depletion of CD25 regulatory T cells enhance tumour immunity of dendritic cell-based vaccine in a mouse model of colon cancer.

Saha A, Chatterjee SK.

Scand J Immunol. 2010 Feb;71(2):70-82. doi: 10.1111/j.1365-3083.2009.02355.x.

PMID:
20384858
[PubMed - indexed for MEDLINE]
13.

The therapeutic potential of 4-1BB (CD137) in cancer.

Nam KO, Kang WJ, Kwon BS, Kim SJ, Lee HW.

Curr Cancer Drug Targets. 2005 Aug;5(5):357-63. Review.

PMID:
16101383
[PubMed - indexed for MEDLINE]
14.

The mechanism of anti-CTLA-4 activity and the negative regulation of T-cell activation.

Wolchok JD, Saenger Y.

Oncologist. 2008;13 Suppl 4:2-9. doi: 10.1634/theoncologist.13-S4-2. Review.

PMID:
19001145
[PubMed - indexed for MEDLINE]
Free Article
15.

Anti-cytotoxic T lymphocyte antigen-4 (CTLA-4) immunotherapy for the treatment of prostate cancer.

Thompson RH, Allison JP, Kwon ED.

Urol Oncol. 2006 Sep-Oct;24(5):442-7. Review.

PMID:
16962497
[PubMed - indexed for MEDLINE]
Free PMC Article
16.

Immune checkpoint proteins: a new therapeutic paradigm for cancer--preclinical background: CTLA-4 and PD-1 blockade.

Weber J.

Semin Oncol. 2010 Oct;37(5):430-9. doi: 10.1053/j.seminoncol.2010.09.005. Review.

PMID:
21074057
[PubMed - indexed for MEDLINE]
17.

Targeting costimulatory pathways for tumor immunotherapy.

Ward RC, Kaufman HL.

Int Rev Immunol. 2007 May-Aug;26(3-4):161-96. Review.

PMID:
17558743
[PubMed - indexed for MEDLINE]
18.

Potentiation of therapeutic immune responses against malignancies with monoclonal antibodies.

Murillo O, Arina A, Tirapu I, Alfaro C, Mazzolini G, Palencia B, López-Diaz De Cerio A, Prieto J, Bendandi M, Melero I.

Clin Cancer Res. 2003 Nov 15;9(15):5454-64. Review.

PMID:
14654524
[PubMed - indexed for MEDLINE]
Free Article
19.

The role of antigen-specific and non-specific immunotherapy in the treatment of cancer.

Monjazeb AM, Hsiao HH, Sckisel GD, Murphy WJ.

J Immunotoxicol. 2012 Jul-Sep;9(3):248-58. doi: 10.3109/1547691X.2012.685527. Epub 2012 Jun 26. Review.

PMID:
22734880
[PubMed - indexed for MEDLINE]
20.

Overcoming immunosuppressive mechanisms.

Widén K, Mozaffari F, Choudhury A, Mellstedt H.

Ann Oncol. 2008 Sep;19 Suppl 7:vii241-7. doi: 10.1093/annonc/mdn459. No abstract available.

PMID:
18790959
[PubMed - indexed for MEDLINE]
Free Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk